Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines

Journal of Orthopaedic Research

Volumn 30, Issue 7, 2012, Pages 1045-1050

  Sakai, Toshinori ^a   Eskander, Ramez N ^a   Guo, Yi ^a   Kim, Kap Jung ^a   Mefford, Jason ^a   Hopkins, Justin ^a   Bhatia, Nitin N ^a   Zi, Xiaolin ^b   Hoang, Bang H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

apoptosis; flavokawain; synovial sarcoma

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CHALCONE; DEATH RECEPTOR 5; DRUG VEHICLE; FLAVOKAWAIN B; KAVA EXTRACT; MESSENGER RNA; MITOCHONDRIAL PROTEIN; PUMA PROTEIN; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SYNOVIAL SARCOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CHALCONE; ENDOMETRIUM; FEMALE; FIBROBLASTS; FLAVONOIDS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KAVA; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS;

EID: 84861101985     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22050     Document Type: Article

References (19)

1. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. 1999. Synovial sarcoma: identification of low and high risk groups. Cancer 85: 2596-2607.
2. Eilber FC, Brennan MF, Eilber FR, et al. 2007. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 246: 105-113.
3. Joyner DE, Bastar JD, Randall RL,. 2006. Doxorubicin induces cell senescence preferentially over apoptosis in the FU-SY-1 synovial sarcoma cell line. J Orthop Res 24: 1163-1169.
4. Lewis JJ, Antonescu CR, Leung DH, et al. 2000. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 18: 2087-2094.
5. Singh YN,. 1992. Kava: an overview. J Ethnopharmacol 37: 13-45.
6. Steiner GG,. 2000. The correlation between cancer incidence and kava consumption. Hawaii Med J 59: 420-422.
7. Tang Y, Li X, Liu Z, et al. 2010. Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int J Cancer 127: 1758-1768.
8. Lin E, Lin WH, Wang SY, et al. 2011. Flavokawain B inhibits growth of human squamous carcinoma cells: involvement of apoptosis and cell cycle dysregulation in vitro and in vivo. J Nutr Biochem [Epub ahead of print].
9. Yano T, Yamazaki Y, Adachi M, et al. 2011. Tara up-regulates E-cadherin transcription by binding to the Trio RhoGEF and inhibiting Rac signaling. J Cell Biol 193: 319-332.
10. Häcker G,. 2000. The morphology of apoptosis. Cell Tissue Res 301: 5-17.
11. Finnberg N, El-Deiry WS,. 2008. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 7: 1525-1528.
12. Kim H, Rafiuddin-Shah M, Tu HC, et al. 2006. Hierarchical regulation of mitochondrial dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8: 1348-1358.
13. Ho PK, Hawkins CJ,. 2005. Mammalian initiator apoptotic caspases. FEBS J 272: 5436-5453.
14. Wang W, Kim SH, El-Deiry WS,. 2006. Small molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 103: 11003-11008.
15. Oda Y, Sakamoto A, Saito T, et al. 2000. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Mod Pathol 13: 994-1004.
16. Schneider-Stock R, Onnasch D, Haeckel C, et al. 1999. Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Arch 435: 407-412.
17. Gavathiotis E, Suzuki M, Davis ML, et al. 2008. BAX activation is initiated at a novel interaction site. Nature 455: 1076-1081.
18. Centers for Disease Control and Prevention. 2003. Hepatic toxicity possibly associated with kava-containing products€"United States, Germany, and Switzerland, 1999-2002. JAMA 289: 36-37.
19. Centers for Disease Control and Prevention. 2002. Hepatic toxicity possibly associated with kava-containing products€"United States, Germany, and Switzerland, 1999-2002. MMWR 51: 1065-1067.